Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma
N/A
25 Years
85 Years
25 Years
85 Years
Open (Enrolling)
Both
Lung Adenocarcinoma
Both
Lung Adenocarcinoma
Trial Information
Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma
Inclusion Criteria:
- Lung cancer received operation lobectomy in CMUH
Exclusion Criteria:
- History of uremia, other malignant disease, and liver cirrhosis
- History of pneumonia and pulmonary tuberculosis
- History of long period of medications.
Type of Study:
Observational
Study Design:
Time Perspective: Retrospective
Authority:
Taiwan: Institutional Review Board
Study ID:
DMR99-IRB-096
NCT ID:
NCT01249066
Start Date:
September 2010
Completion Date:
Related Keywords:
- Lung Adenocarcinoma
- AMP-activated protein kinase
- lung adenocarcinomas
- Prognosis
- Observation study
- Adenocarcinoma
- Adenocarcinoma, Mucinous
- Lung Neoplasms
Name | Location |
|---|
